Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BAO FENG BIOTECH (BEIJING) CO., LTD currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between distinct examiners and distinct art units, which distributes the work within the patent office. This variety suggests that the company's innovations are being evaluated across distinct technical niches or by separate sets of eyes. The busiest examiner, MACFARLANE, STACEY NEE, is responsible for 1 busiest examiner pending action.
While there are 2 pending office actions in total, the workload is distributed, as the busiest examiner handles this specific case while the remaining workload is assigned elsewhere. This means that the distinct examiners share the pending matters, providing the company with varied points of interaction in the Biotechnology & Pharmaceuticals sector. Because the portfolio involves distinct art units, the prosecution strategy must account for potentially varied examination cultures or guidelines.
The pending office actions require separate attention, as the distinct examiners may have varied interpretations of the prior art. Successfully managing the 1 busiest examiner pending action is a part of the broader effort to navigate the distinct art units currently active.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021229 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID AND USE THEREOF | FRITCHMAN, REBECCA M | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021229 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID AND USE THEREOF | FRITCHMAN, REBECCA M | 6d |
| 18021211 | METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF | MACFARLANE, STACEY NEE | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021229 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID AND USE THEREOF | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 6d | Pending | Feb 14, 2023 |
| 18021211 | METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF | MACFARLANE, STACEY NEE | 1675 | §103DP | Non-Final OA | — | Pending | Feb 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial